Summary by Moomoo AI
On April 23, 2024, Senti Biosciences Inc., a Delaware-incorporated biotechnology company, announced the resignation of its Chief Financial Officer, Treasurer, and Head of Corporate Development, Deborah Knobelman, Ph.D., effective May 3, 2024. Dr. Knobelman's departure is not due to any disagreements with the company's operations, policies, or practices. Following her resignation, Dr. Knobelman will enter into a consulting agreement with Senti Biosciences starting May 4, 2024, to assist with the transition of her responsibilities. She will receive a maximum payment of $60,000 for her services. Senti Biosciences is actively searching for an interim CFO and treasurer. The company plans to file the full Knobelman Consulting Agreement with its upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. The report also includes forward-looking statements regarding the search for new financial leadership and acknowledges the risks and uncertainties inherent in the market and the company's SEC filings.